Raymond James Starts Alpha Cognition (ACOG) at Outperform

Alpha Cognition Inc. (NASDAQ:ACOG) is one of the 10 High Growth Stocks Insiders Are Buying.

On July 10, 2026, Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition Inc. (NASDAQ:ACOG) with an Outperform rating and $20 price target. Deschner noted that Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer’s disease.

Deschner said Zunveyl is designed to address a large unmet need in Alzheimer’s disease, including gastrointestinal tolerability and other adverse events that are a primary source of discontinuation for the most commonly prescribed class of Alzheimer’s disease drugs, acetylcholinesterase inhibitors.

On June 24, Alpha Cognition Inc. (NASDAQ:ACOG) announced changes to its Board of Directors. Robert Wills was elected Chairman of the Board, succeeding Len Mertz, who retired from the Board.

Raymond James Starts Alpha Cognition (ACOG) at Outperform

Miriam Doerr Martin Frommherz/Shutterstock.com

On June 16, Alpha Cognition announced enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The study is expected to enroll approximately 150 patients across multiple clinical sites and monitor adverse events, treatment persistence, and discontinuation rates.

Alpha Cognition Inc. (NASDAQ:ACOG) develops treatments for patients suffering from neurodegenerative diseases in the United States and Canada.

While we acknowledge the risk and potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ACOG and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1